Author/Authors :
Bergmann-Leitner، نويسنده , , Elke S. and Abrams، نويسنده , , Scott I.، نويسنده ,
Abstract :
The influence of a human CD4+ T cell response in anti-carcinoma immune reactions remains largely uncharacterized. Here, we made use of a major histocompatibility complex (MHC) class-II-restricted, anti-ras oncogene-specific CD4+ T cell line produced previously in vivo from a patient with metastatic carcinoma in a peptide-based phase I trial. Using this patient-derived T cell line as a potentially relevant cell type, we examined the consequences of the anti-carcinoma CD4+ T cell response, with emphasis on specific lymphokines potentially important for the regulation of Fas/Fas ligand (FasL) interactions. Antigen (Ag)-specific CD4+ T cells produced substantial amounts of IFN-γ following recognition of MHC class-II-matched Ag-presenting cells expressing the cognate peptide. The IFN-γ promoted significant upregulation of Fas on the surface of colon carcinoma cells and sensitized these targets to Fas-mediated apoptosis and Ag-specific CD8+ cytotoxic T lymphocyte (CTL)-mediated lysis involving a Fas-based effector mechanism. Moreover, Ag-stimulated CD4+ T cells secreted soluble FasL (sFasL), which induced the death of TNF-resistant/refractory colon, breast, and ovarian carcinoma cells. Interestingly, although CD4+-derived sFasL expressed cytotoxic activity, the recovery of carcinoma cells which resisted Fas-mediated lysis displayed enhanced metastatic ability in vivo, compared with the unselected parental population, in an athymic mouse model. Thus, a tumor-specific CD4+ T cell response may have both positive and negative consequences in human carcinoma via the production of proinflammatory cytokines such as IFN-γ and/or sFasL that may (1) improve or facilitate CTL–target engagement, contact-independent effector mechanisms, and the overall lytic outcome and (2) potentially select for Fas-resistant tumor cells that escape immune destruction, which may thus impact the metastatic process.
Keywords :
human , cytotoxicity , oncogenes , Tumor Immunity , CD4+ T cells